BioSpace News Archive

Innovent Biologics, Inc. announced that the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in a poster presentation at the American Association for Cancer Research Annual Meeting 2023.

Abbisko announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research annual meeting.

Adela, Inc. presented data demonstrating the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages, when treatment can be most effective.

Volastra Therapeutics released preclinical data from the company’s portfolio of KIF18A inhibitors at the 2023 American Association for Cancer Research Annual Meeting in Orlando.

Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer.

Vivace Therapeutics, Inc. announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research Annual Meeting 2023.

Telix Pharmaceuticals Limited announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company.

MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi® plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Vaxcyte, Inc. announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies.

As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in China.